drugset / Trial / NCT05184569
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
Phase 1
Active not recruiting
64 enrolled
Peter Ljubenkov, MD
Alzheimer's Association · collabNational Institute on Aging (NIA) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Timeline
- Start
- 2022-04-14
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Verdiperstat | Small molecule | 600 mg | Oral |